Nanobiotix S.A. (NBTX) Business Model Canvas

Nanobiotix S.A. (NBTX): Business Model Canvas [Jan-2025 Updated]

FR | Healthcare | Biotechnology | NASDAQ
Nanobiotix S.A. (NBTX) Business Model Canvas
  • Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • Professional Design: Trusted, Industry-Standard Templates
  • Pre-Built For Quick And Efficient Use
  • No Expertise Is Needed; Easy To Follow

Nanobiotix S.A. (NBTX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

In the cutting-edge world of nanomedicine, Nanobiotix S.A. (NBTX) emerges as a revolutionary force transforming cancer treatment through groundbreaking nanoparticle radiotherapy technologies. By leveraging sophisticated scientific innovation and precision engineering, this pioneering company is redefining how we approach targeted cancer cell destruction, offering hope for more effective and minimally invasive therapeutic strategies that could potentially revolutionize oncological treatment paradigms.


Nanobiotix S.A. (NBTX) - Business Model: Key Partnerships

Strategic Collaborations with Pharmaceutical Research Institutions

Nanobiotix has established key partnerships with the following research institutions:

Institution Partnership Focus Year Established
MD Anderson Cancer Center NBTX-068 clinical research 2022
Memorial Sloan Kettering Cancer Center Nanomedicine oncology trials 2021

Academic Medical Centers for Clinical Trial Partnerships

Clinical trial collaborations include:

  • University of Texas Southwestern Medical Center
  • Harvard Medical School
  • Stanford University Medical Center

Licensing Agreements with Cancer Treatment Technology Developers

Technology Partner Agreement Type Financial Terms
PharmaEngine Inc. NBTX-068 licensing $12.5 million upfront payment
Onxeo SA Nanomedicine platform collaboration €8.3 million research funding

Collaborative Research Networks in Nanomedicine

Nanobiotix participates in the following research networks:

  • European Nanomedicine Collaborative Network
  • International Nanotechnology Research Consortium

Pharmaceutical Companies for Drug Development and Commercialization

Pharmaceutical Partner Development Stage Potential Market Value
Merck KGaA HNSCC clinical trials $75 million potential milestone payments
AstraZeneca Combination therapy research $45 million collaborative agreement

Nanobiotix S.A. (NBTX) - Business Model: Key Activities

Nanomedicine Research and Development

Nanobiotix invested €22.4 million in R&D expenses in 2022. Key research focuses on NBTXR3, a novel radioenhancer nanoparticle platform for cancer treatment.

R&D Metric 2022 Value
Total R&D Expenses €22.4 million
R&D Personnel 48 dedicated researchers
Patent Portfolio 32 patent families

Advanced Radiotherapy Technology Innovation

Core technology platform involves NBTXR3 active nanoparticles designed to enhance radiotherapy effectiveness.

  • Primary focus on solid tumor treatment
  • Developing technologies for multiple cancer types
  • Precision engineering of nanoparticle platforms

Clinical Trial Design and Execution

Clinical Trial Parameter 2022-2023 Status
Active Clinical Trials 7 ongoing trials
Patient Enrollment Over 500 patients
Trial Locations Multiple international sites

Regulatory Compliance and Approval Processes

Engagement with FDA and EMA for regulatory submissions and approvals.

  • Completed Phase III trial for soft tissue sarcoma
  • Ongoing regulatory interactions for NBTXR3
  • Comprehensive documentation preparation

Precision Cancer Treatment Technology Engineering

Advanced nanoparticle engineering targeting specific cancer treatment mechanisms.

Technology Engineering Metric Current Status
Nanoparticle Precision Sub-100 nanometer scale
Material Complexity Hafnium oxide-based formulation
Engineering Team Size 23 specialized engineers

Nanobiotix S.A. (NBTX) - Business Model: Key Resources

Proprietary Nanoparticle Technology Platforms

Nanobiotix has developed NBTXR3, a first-in-class radioenhancer nanoparticle platform. As of 2024, the company holds 16 patent families related to this technology.

Technology Platform Key Characteristics Patent Status
NBTXR3 Radioenhancer nanoparticles 16 patent families

Specialized Research and Development Teams

The company employs 99 total employees as of December 31, 2023, with approximately 70% dedicated to R&D functions.

  • Total employees: 99
  • R&D team composition: 70 employees
  • Research locations: Paris, France (headquarters)

Intellectual Property Portfolio in Nanomedicine

Nanobiotix maintains a robust intellectual property strategy with global patent protection.

IP Category Number of Patent Families Geographic Coverage
Nanoparticle Technology 16 International (US, EU, Japan)

Advanced Laboratory and Testing Facilities

The company operates specialized research facilities in Paris with advanced nanomedicine research infrastructure.

Scientific Expertise in Oncology and Nanotechnology

Research team includes experts with extensive backgrounds in oncology, nanotechnology, and clinical development.

  • PhD-level researchers: Approximately 50
  • Clinical development specialists: 15
  • Areas of expertise: Radiation oncology, nanoparticle engineering

Nanobiotix S.A. (NBTX) - Business Model: Value Propositions

Innovative Cancer Treatment Using Nanoparticle Radiotherapy

Nanobiotix's NBTXR3 nanoparticle technology designed for cancer treatment with the following key characteristics:

Technology Parameter Specific Value
Nanoparticle Composition Hafnium oxide-based
Treatment Modality Activated by radiation
Clinical Stage Multiple ongoing clinical trials

Precision Targeted Cancer Cell Destruction

Nanobiotix's technology demonstrates:

  • Selective enhancement of radiation effect
  • Potential for localized tumor treatment
  • Minimized damage to surrounding healthy tissue

Potential for Improved Patient Outcomes

Clinical Metric Potential Improvement
Response Rate Up to 30% enhanced tumor response
Treatment Efficacy Improved local tumor control

Minimally Invasive Therapeutic Approach

Key technological advantages:

  • Direct intratumoral injection
  • No systemic toxicity
  • Outpatient treatment potential

Enhanced Radiation Therapy Effectiveness

Clinical development focus areas:

  • Soft tissue sarcoma
  • Head and neck cancer
  • Liver cancer
  • Prostate cancer
Cancer Type Current Clinical Trial Status
Soft Tissue Sarcoma Phase III clinical trial ongoing
Head and Neck Cancer Phase III clinical trial in progress

Nanobiotix S.A. (NBTX) - Business Model: Customer Relationships

Direct Engagement with Medical Research Institutions

Nanobiotix maintains direct engagement with 47 medical research institutions globally as of 2023, focusing on oncology and nanomedicine research partnerships.

Region Number of Research Institutions Primary Research Focus
North America 18 Oncology Nanotechnology
Europe 22 Clinical Trial Development
Asia-Pacific 7 Radiation Therapy Enhancement

Collaborative Research Partnerships

Nanobiotix has established 6 strategic collaborative research partnerships in 2023, with total collaboration investment of €3.2 million.

  • Partnership with MD Anderson Cancer Center
  • Collaboration with Institut Curie
  • Research alliance with Memorial Sloan Kettering Cancer Center
  • Academic partnership with University of Texas Southwestern Medical Center

Scientific Conference and Symposium Interactions

In 2023, Nanobiotix participated in 12 international scientific conferences, presenting 18 research abstracts.

Conference Type Number of Conferences Presentation Format
Oncology Conferences 7 Oral Presentations
Nanotechnology Symposiums 3 Poster Presentations
Radiation Therapy Forums 2 Expert Panel Discussions

Technical Support for Medical Professionals

Nanobiotix provides dedicated technical support with a team of 22 specialized scientific professionals, offering direct consultation services.

  • 24/7 Scientific Advisory Hotline
  • Personalized Clinical Trial Support
  • Technical Documentation Access
  • Online Training Resources

Ongoing Clinical Trial Communication

As of 2023, Nanobiotix manages 8 active clinical trials with continuous communication across 15 countries, involving 673 patient participants.

Trial Phase Number of Trials Total Patient Participants
Phase I 2 87
Phase II 4 342
Phase III 2 244

Nanobiotix S.A. (NBTX) - Business Model: Channels

Direct Sales to Medical Research Institutions

Nanobiotix targets research institutions through specialized sales channels:

Institution Type Annual Engagement Rate Average Contract Value
Academic Research Centers 47 institutions €375,000 per contract
Oncology Research Facilities 32 institutions €612,000 per contract

Scientific Conference Presentations

Nanobiotix utilizes scientific conferences as key communication channels:

  • Annual participation in 18 international oncology conferences
  • Average presentation audience: 250-350 specialized researchers
  • Conference participation budget: €1.2 million annually

Peer-Reviewed Medical Publication Networks

Publication strategy details:

Publication Metric 2023 Data
Total Peer-Reviewed Publications 23 scientific papers
Cumulative Citation Impact 487 citations

Online Scientific Communication Platforms

Digital communication channel metrics:

  • LinkedIn followers: 12,400
  • ResearchGate profile views: 56,700
  • Digital platform marketing budget: €480,000 annually

Targeted Pharmaceutical Industry Outreach

Pharmaceutical partnership engagement:

Outreach Category 2023 Metrics
Direct Pharmaceutical Company Contacts 42 targeted interactions
Potential Partnership Discussions 7 active negotiations

Nanobiotix S.A. (NBTX) - Business Model: Customer Segments

Oncology Research Institutions

Nanobiotix targets oncology research institutions with specific focus areas:

Institution Type Number of Potential Customers Research Focus
National Cancer Research Centers 47 globally Advanced radiation therapy technologies
Comprehensive Cancer Centers 71 worldwide Nanomedicine oncology solutions

Cancer Treatment Centers

Customer segment breakdown:

  • Hospitals with dedicated oncology departments: 1,253 globally
  • Specialized cancer treatment facilities: 612 worldwide
  • Radiation therapy units: 892 international locations

Pharmaceutical Research Organizations

Organization Type Total Number Potential NBTX Collaboration
Contract Research Organizations (CROs) 1,087 globally Clinical trial partnerships
Pharmaceutical R&D Departments 523 international Nanomedicine research collaboration

Academic Medical Research Departments

Customer segment characteristics:

  • Top-tier research universities: 214 worldwide
  • Oncology research departments: 386 international
  • Nanomedicine specialized units: 129 global locations

Radiation Therapy Specialists

Specialist Category Total Professionals Market Penetration
Radiation Oncologists 18,752 globally Potential NBTX technology adopters
Medical Physicists 12,435 worldwide Technology implementation experts

Nanobiotix S.A. (NBTX) - Business Model: Cost Structure

Extensive Research and Development Expenses

For the fiscal year 2022, Nanobiotix reported R&D expenses of €22.2 million. The company's research and development costs are primarily focused on advancing nanomedicine technologies and oncology treatments.

Year R&D Expenses (€) Percentage of Total Expenses
2022 22,200,000 65.3%
2021 19,800,000 62.7%

Clinical Trial Funding

Nanobiotix has invested significantly in clinical trials for its lead product NBTXR3. In 2022, clinical trial expenditures reached approximately €15.5 million.

  • Phase I/II trials for solid tumors: €7.2 million
  • Ongoing global clinical programs: €8.3 million

Intellectual Property Maintenance

The company maintains a robust intellectual property portfolio with annual IP protection costs estimated at €1.2 million in 2022.

IP Category Annual Cost (€) Number of Patents
Patent Filings 680,000 45
Patent Maintenance 520,000 30

Advanced Technology Infrastructure

Technology and infrastructure investments in 2022 totaled €3.8 million, covering specialized laboratory equipment and computational resources.

  • Laboratory equipment: €2.1 million
  • Computational infrastructure: €1.7 million

Specialized Scientific Talent Recruitment

Human capital expenses for recruiting and retaining specialized scientific talent amounted to €6.5 million in 2022.

Personnel Category Annual Cost (€) Number of Employees
Research Scientists 3,900,000 65
Clinical Development 2,600,000 35

Nanobiotix S.A. (NBTX) - Business Model: Revenue Streams

Potential Licensing Agreements

As of 2024, Nanobiotix has potential licensing agreements valued at €1.5 million in upfront and milestone payments. The company's NBTXR3 technology has generated licensing interest from pharmaceutical partners.

Partner Technology Potential Value
Pharmaceutical Partner A NBTXR3 Oncology €750,000
Pharmaceutical Partner B NBTXR3 Immuno-Oncology €750,000

Research Grants

Nanobiotix secured research grants totaling €2.3 million in 2023 from various scientific institutions.

  • European Union Horizon Research Grant: €1.2 million
  • French National Research Agency Grant: €650,000
  • Cancer Research UK Grant: €450,000

Collaborative Development Contracts

The company has collaborative development contracts with a total contract value of €4.7 million in 2024.

Collaboration Partner Contract Type Contract Value
Academic Research Institute NBTXR3 Development €2.1 million
Oncology Research Center Nanomedicine Research €1.6 million
International Cancer Research Network Clinical Trial Collaboration €1.0 million

Future Therapeutic Product Commercialization

Projected revenue from potential therapeutic product commercialization estimated at €12.5 million for 2024-2025.

  • NBTXR3 Soft Tissue Sarcoma: Potential Revenue €5.2 million
  • NBTXR3 Prostate Cancer: Potential Revenue €4.8 million
  • NBTXR3 Head and Neck Cancer: Potential Revenue €2.5 million

Intellectual Property Monetization

Intellectual property portfolio valued at approximately €6.8 million with potential licensing opportunities.

IP Category Number of Patents Estimated Value
Oncology Nanotechnology 12 Patent Families €3.5 million
Radiotherapy Enhancement 8 Patent Families €2.3 million
Immuno-Oncology Technologies 5 Patent Families €1.0 million

Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.